Overview

Gemcitabine and Dasatinib in Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of dasatinib in combination with gemcitabine that can be given to patients with advanced solid tumors. The safety of this combination of study drugs will also be studied. Researchers also want to study the pharmacodynamics (PDs) of this study drug combination. PD testing is used to learn what effect the drugs have on your tumors.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
Dasatinib
Gemcitabine